Article

Mark Zitter Addresses How Oncology Payers Are Becoming Stricter About Covered Therapies

Mark Zitter, Founder and CEO of The Zitter Group, in San Francisco and Millburn, NJ, discusses how oncology payers are tightening the reins with approval requirements and the delicacy involved in revising guidelines around cancer care.

Mr. Zitter talks about several of the payers' changes, which include prior authorizations, clinical guidelines, and decision-support programs. He also addresses the ongoing friction between payers and providers and how critical it is to find resolution.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Sundar Jagannath
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
Hadar Avihai Lev-Tov, MD
Ayodeji Adegunsoye, MD, PhD, MSc
David J. Maron, MD, FASPC, Stanford University School of Medicine
Hadar Avihai Lev-Tov, MD
Senator Vincent Polistina (R, New Jersey)
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo